The escalating costs of life-saving medications in the U.S. healthcare system have once again been brought to the forefront by U.S. Senator Bernie Sanders (I-Vt.). Sanders has targeted pharmaceutical giant Novo Nordisk for charging over $900 a month for the diabetes drug Ozempic, a price tag that could be as low as $100 if sold by generic manufacturers. As the chair of the Senate Health, Education, Labor, and Pensions (HELP) Committee, Sanders has called out what he terms “excessive corporate greed,” accusing Novo Nordisk of exploiting American patients while making billions in profits.
Novo Nordisk’s pricing practices have sparked outrage, as their drugs Ozempic and Wegovy dominate a growing market. Ozempic, which treats Type 2 diabetes, costs U.S. patients an average of $969 per month. Wegovy, marketed as a weight-loss drug, carries an even higher price tag of $1,349. Sanders pointed out that the cost of these drugs is far lower in other countries, raising questions about why Americans are paying more than anyone else in the world.
Ozempic and Wegovy are part of a class of drugs known as GLP-1 agonists, which are designed to treat diabetes and, more recently, obesity. Although the medications share the same active ingredient, they are marketed separately for different medical purposes. Yet, what stands out most is the stark price difference between the U.S. and other countries.
While Americans are paying nearly $1,000 a month for Ozempic, the same drug costs $155 in Canada, $122 in Denmark, and just $59 in Germany. Wegovy’s price disparity is even more glaring, with the drug sold for $186 in Denmark, $140 in Germany, and $92 in the United Kingdom. These figures highlight a global inequality in drug pricing, with U.S. patients facing the brunt of pharmaceutical price gouging.
Novo Nordisk has made nearly $50 billion in sales from Ozempic and Wegovy, benefiting immensely from high demand and limited competition in the U.S. market. During a recent panel discussion, Sanders did not hold back in his criticism of the company, stating, “Novo Nordisk, which has made nearly $50 billion in sales off of Ozempic and Wegovy, charges Americans almost $1,000 a month—the highest prices in the world. Why? Excessive corporate greed.”
As a longtime critic of the pharmaceutical industry, Sanders has made it his mission to expose drug companies for profiting at the expense of American patients. His office has been in contact with top executives of major drug manufacturers, who have stated they could produce and sell a generic version of Ozempic for less than $100 per month while still turning a profit. This would represent a significant decrease from the nearly $1,000 that U.S. patients currently pay.
A study from Yale University found that Ozempic and Wegovy could be manufactured for as little as $5 per month, a mere fraction of what Novo Nordisk charges. Sanders and his allies argue that such inflated pricing is unsustainable and has placed undue financial pressure on patients and the U.S. healthcare system.
“Our healthcare system, I think most people understand, is in crisis,” Sanders said during the panel discussion. “The business model of the pharmaceutical industry is unsustainable.” He warned that unless the prices of drugs like Ozempic and Wegovy are reined in, the financial burden on programs like Medicare could become overwhelming.
Economists have expressed serious concerns about the impact of Novo Nordisk’s pricing on the broader healthcare system. A group of economists recently estimated that, under current pricing, making GLP-1 drugs like Ozempic and Wegovy available to all obese Americans could cost over $1 trillion per year. This is nearly equivalent to what the federal government spends on the entire Medicare program and would represent one-fifth of America’s total healthcare spending.
The high prices of these drugs have significant implications for Medicare. If drug prices remain unchecked, Medicare premiums could surge, placing an even greater financial burden on taxpayers. Public health advocates have warned that Novo Nordisk’s pricing model could “break the coffers” of federal health programs like Medicare and Medicaid, which would struggle to cover the cost of these expensive medications.
Peter Maybarduk, director of the Access to Medicines Program at Public Citizen, echoed these concerns, saying, “All we need to make Ozempic for $100 a reality is to overcome Novo’s patent monopoly, which the government has the power to do any time.” Public Citizen has been at the forefront of efforts to push for government intervention, urging U.S. Health and Human Services Secretary Xavier Becerra to authorize generic competitors under existing laws. Such action, Maybarduk estimates, could save Medicare more than $14 billion in just two years.
Public Citizen and other advocacy groups are pressuring the U.S. government to use legal mechanisms to break Novo Nordisk’s patent monopoly. Last month, Public Citizen delivered a petition to Health and Human Services, calling for the use of 28 U.S.C. § 1498, which would allow the government to authorize the production of generic alternatives to patented drugs, including Ozempic and Wegovy. This would create competition in the market, driving prices down and making these essential drugs more accessible to patients.
As the Senate HELP Committee prepares to hold a hearing with Novo Nordisk’s CEO, Lars Jørgensen, the pressure is mounting on the pharmaceutical giant to explain its pricing practices. Both Sanders and President Joe Biden have made it clear that if drug companies do not lower prices voluntarily, they will take steps to force change. In a statement co-authored by Sanders and Biden earlier this year, they warned, “If Novo Nordisk and other pharmaceutical companies refuse to substantially lower prescription drug prices in our country and end their greed, we will do everything within our power to end it for them.”
With millions of Americans relying on medications like Ozempic for their health, it is clear that change is needed. As Sanders put it, “Our healthcare system, I think most people understand, is in crisis. The business model of the pharmaceutical industry is unsustainable.”
COMMENTS